Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Sep 23, 2010
Vertex Pharmaceuticals (NASDAQ:VRTX) priced a public offering of $375 million in convertible senior subordinated notes Thursday.
Shares of Vertex Pharmaceuticals fell 1.5% in early trading Thursday.
SmarTrend currently has Vertex Pharmaceuticals in an Uptrend and is currently monitoring these developments and will alert subscribers to any change of trend.
Vertex Pharmaceuticals Incorporated discovers, develops, and commercializes novel, small molecule pharmaceuticals for the treatment of diseases for which there are currently limited or no effective treatments. The Company is developing drugs for the treatment of viral diseases, multidrug resistance in cancer, inflammatory and autoimmune diseases, and neurodegenerative diseases.